Clinical Trials Directory

Trials / Completed

CompletedNCT04622891

Clarithromycin Versus Azithromycin in Treatment of Mild COVID-19 Infection

Efficacy of Clarithromycin in Comparison to Azithromycin in Treatment of Mild COVID-19 Infection, Randomized Controlled Trial

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
300 (actual)
Sponsor
South Valley University · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

The current study was conducted at Qena Governorate, Egypt, during the period from May 2020, to July 2020. The study included 305 COVID-19 cases diagnosed by PCR, patients were randomly assigned to one of three study limps, Azithromycin 500 mg/24 h for 7 days, Clarithromycin 500 /12 h for 7 days, or a control group with no antibiotics, All three groups received only symptomatic treatment for control of fever and cough

Detailed description

The current study was conducted at Qena Governorate, Egypt, during the period from May 2020, to July 2020. The study included 305 COVID-19 cases diagnosed by PCR, patients were randomly assigned to one of three study limps, Azithromycin 500 mg/24 h for 7 days, Clarithromycin 500 /12 h for 7 days, or a control group with no antibiotics, All three groups received only symptomatic treatment for control of fever and cough. All study participants underwent full clinical evaluation including duration of fever, cough, dyspnea, anosmia or GIT symptoms, C-reactive protein (CRP), serum ferritin, D-dimer, Complete blood count (CBC), non-contrast chest computed tomography (CT) which was repeated 2 weeks after the start of treatment. The Azithromycin group included, 107 patients, mean age 45.8 ±18 years, 73 male and 34 female, the Clarithromycin group included 99 patients mean age 46.1±19 years, 68 males and 31 female, the control group included 99 patients, with mean age 41.1 ± 18 years, 73 male and 28 female.

Conditions

Interventions

TypeNameDescription
DRUGClarithromycin 500mgclarithromycin 500
DRUGAzithromycinazithromycin group
DRUGPlacebocontrol group

Timeline

Start date
2020-04-01
Primary completion
2020-07-30
Completion
2020-07-30
First posted
2020-11-10
Last updated
2020-11-10

Locations

1 site across 1 country: Egypt

Source: ClinicalTrials.gov record NCT04622891. Inclusion in this directory is not an endorsement.